OKYO Pharma

OKYO Pharma

OKYO Pharma Ltd was incorporated in 2007 and is headquartered in London, with a clinical development focus on dry eye disease and other ocular indications. Gary S. Jacob has served as CEO, steering the company toward a niche in ophthalmology where the addressable market remains large and unmet need is high. The firm operates as a publicly traded specialty pharmaceutical company, not a diversified investment platform. Its strategy concentrates on advancing a lead candidate, OK-101, through clinical trials. OK-101 is a lipidated chemerin peptide designed to target inflammation associated with dry eye disease, with Phase 2 data reported in 2022 and 2023 showing statistically significant improvements in both signs and symptoms. The company also holds earlier-stage genetic assets targeting inflammatory pathways. In February 2025, OKYO completed an underwritten public offering raising gross proceeds of roughly $4.8 million to support ongoing clinical and regulatory work. As of mid-2025, OKYO operates a lean corporate structure typical of a clinical-stage biotech, with key management based in the US and UK and research functions supported by contracted partners. No professional headcount or AUM is publicly disclosed; corporate spending maps directly to trial costs. In the past 24 months, the company has reported top-line Phase 2 results for OK-101 (December 2023) and secured additional equity financing. OKYO’s structural distinction lies in its almost singular pipeline focus on the anterior segment of the eye, an area often overlooked by larger pharmaceutical platforms that prioritize retinal gene therapies. The company’s fate is tied directly to the regulatory and clinical milestones of OK-101, making it a pure-play bet on a single mechanism of action in a well-defined market.